Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nutrinamin is a dietary supplement distributed by Hygis in Switzerland, primarily indicated for the support of urinary tract health and the maintenance of normal mucous membranes. The product features a synergistic combination of D-mannose, cranberry extract (standardized for proanthocyanidins), Vitamin C (ascorbic acid), and Biotin. D-mannose acts as a competitive inhibitor of bacterial adhesion by binding to the FimH adhesins of uropathogenic *Escherichia coli*, preventing the bacteria from attaching to the bladder wall and facilitating their clearance through urination. Cranberry proanthocyanidins similarly inhibit bacterial P-fimbriae. Vitamin C contributes to the normal function of the immune system and helps acidify the urine, while Biotin supports the integrity and maintenance of healthy vaginal and urinary mucous membranes. It is typically marketed as an oral powder for solution.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nutrinamin.